Tilray Brands (TLRY) Profit After Tax (2017 - 2026)
Tilray Brands (TLRY) posted Profit After Tax of -$29.9 million for Q1 2026, up 23.37% on a QoQ basis from -$39.0 million in Q4 2025, and up 96.21% year-over-year from -$15.2 million in Q1 2025.
Tilray Brands (TLRY) Profit After Tax (2017 - 2026) Analysis & Trends
Tilray Brands' Profit After Tax history runs 10 years deep, the most recent figure standing at -$29.9 million for Q1 2026.
- Quarterly Profit After Tax rose 96.21% year-over-year to -$29.9 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was -$1.3 billion (down 43.62% YoY) and the FY2025 annual result came in at -$2.2 billion, down 897.02% from the prior year.
- Profit After Tax was -$29.9 million for Q1 2026 at Tilray Brands, up from -$39.0 million in the prior quarter.
- Across five years, Profit After Tax topped out at $43.2 million in Q1 2022 and bottomed at -$1.3 billion in Q2 2025.
- A 5-year average of -$202.3 million and a median of -$52.7 million in 2023 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2022 — Profit After Tax soared 115.79% — and 2024, when it plunged 17597.17%.
- Tilray Brands' Profit After Tax stood at -$103.9 million in 2022, then surged by 60.55% to -$41.0 million in 2023, then tumbled by 129.97% to -$94.2 million in 2024, then soared by 58.57% to -$39.0 million in 2025, then advanced by 23.37% to -$29.9 million in 2026.
- Business Quant data shows TLRY's Profit After Tax at -$29.9 million in Q1 2026, -$39.0 million in Q4 2025, and $1.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 369.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Tilray Brands | 465.02 Mn | 373.06 Mn | 54.95 Mn | -29.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -29.92 Mn |
| Nov 30, 2025 | -39.05 Mn |
| Aug 31, 2025 | 1.33 Mn |
| May 31, 2025 | -1.26 Bn |
| Feb 28, 2025 | -789.44 Mn |
| Nov 30, 2024 | -94.24 Mn |
| Aug 31, 2024 | -30.49 Mn |
| May 31, 2024 | -12.25 Mn |
| Feb 29, 2024 | -104.98 Mn |
| Nov 30, 2023 | -40.98 Mn |
| Aug 31, 2023 | -52.65 Mn |
| May 31, 2023 | -116.50 Mn |
| Feb 28, 2023 | 600,000.00 |
| Nov 30, 2022 | -103.88 Mn |
| Aug 31, 2022 | -132.45 Mn |
| May 31, 2022 | -673.90 Mn |
| Feb 28, 2022 | 43.19 Mn |
| Nov 30, 2021 | -42.88 Mn |
| Aug 31, 2021 | -136.03 Mn |
| May 31, 2021 | 47.20 Mn |